Drawing for BELLA HEALTH

USPTO serial 90451256

BELLA HEALTH

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
BROWNING, LUKE CASH
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BELLA HEALTH?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kimberly S. Grimsley

Kimberly S. Grimsley OLIVER & GRIMSLEY, LLC1 OLYMPIC PLACESUITE 900TOWSON, MD 21204

Goods and services

ClassDescriptionStatusFirst use
005Diagnostic kits comprised of medical diagnostic assays for use in disease detection, screening, treating and monitoring, namely, monitoring COVID-19 and other infectious diseases; Respiratory diagnostic rapid tests, namely, assays for use in performing respiratory rapid tests related to COVID-19 and other infectious diseases; Medical diagnostic screening tests and devices being assays to detect COVID-19 and other infectious diseases in a patientACTIVE—
009Downloadable computer application software for mobile phones, namely, software for covid-19 and other infectious disease identification; Downloadable computer application software for computers, namely, software for covid-19 and other infectious disease identification; Downloadable mobile applications for health screenings relating to COVID-19 and other infectious disease; Downloadable mobile applications for tracking and reporting health conditions and symptoms; Scientific apparatus and instruments, namely, COVID-19 rapid tests for withdrawing and testing respiratory droplets for clinical and medical research, and scientific purposes and structural parts and fittings thereof; Material testing apparatus and instruments, for identifying and testing pathogens and biomarkers in respiratory droplets for clinical, medical, research, and scientific purposes related to COVID-19 and other infectious diseases; Apparatus for transmission of communication; Monitoring, measuring, signaling and control apparatus and instruments for testing respiratory droplets against a panel of biomarkers for clinical, medical, research, and scientific purposes, namely, for COVID-19 and other infectious diseasesACTIVE—
042Providing temporary use of online non-downloadable software for use in the testing and diagnosis of COVID-19, coronavirus, and other diseases; Providing temporary use of online non-downloadable software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Providing temporary use of web-based software applications for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptoms; Software as a service (SAAS) services featuring software for health screenings relating to COVID-19 and other infectious diseases and for tracking and reporting health conditions and symptomsACTIVE—
044Healthcare services; Medical and healthcare information, consultancy and advisory services relating to infections, viruses, SARS-CoV-2, COVID-19, and infectious, viral, communicable, blood borne pathogen, vector borne, pulmonary, respiratory, inflammatory, immunological, autoimmune, rheumatic and cardiovascular diseases and disorders; Providing a web site featuring medical information; Health care services, namely, disease management programs; Telehealth services, namely, providing telemedicine and services in conjunction with providing medical and healthcare services; Mobile healthcare services in the field of Covid and other infectious disease testing, health assessments, intravenous infusion therapy, facilitating appointmentsACTIVE—
045Information collection and management services in the field of public health, namely, collecting, verifying, tracing, tracking, storing, monitoring, and notifying physical sites visited by persons infected with contagious disease for the purpose of slowing or stopping the spread of the disease under the guidance of state and local public health departments; Information collection and management services in the field of public health, namely, collecting, verifying, tracing, tracking, storing, monitoring, and notifying contacts of persons infected with contagious disease for the purpose of slowing or stopping the spread of the disease under the guidance of state and local public health departmentsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jul 12, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 27, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Oct 28, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 26, 2023EX3GSOU EXTENSION 3 GRANTED—
Oct 26, 2023EXT3SOU EXTENSION 3 FILED—
Oct 26, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 15, 2023DOCKASSIGNED TO EXAMINER—
Apr 27, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 25, 2023EX2GSOU EXTENSION 2 GRANTED—
Apr 25, 2023EXT2SOU EXTENSION 2 FILED—
Apr 25, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 19, 2023TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 19, 2023ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 19, 2023REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 28, 2022EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 26, 2022EX1GSOU EXTENSION 1 GRANTED—
Oct 26, 2022EXT1SOU EXTENSION 1 FILED—
Oct 26, 2022EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 26, 2022NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Apr 8, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Apr 8, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 8, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 1, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 1, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 9, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 22, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 16, 2021TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 15, 2021CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 15, 2021TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jun 26, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 26, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 24, 2021DOCKASSIGNED TO EXAMINER—
Apr 6, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 9, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance